Skip to main content

Taconic to Sell Medicyte's Hepatocyte Cell Strains

NEW YORK (GenomeWeb News) – Taconic and Medicyte announced a sales and marketing agreement covering Medicyte's products.

Under the terms of the deal, Taconic will promote and sell Medicyte's human primary Upcyte hepatocyte cell strains and corresponding media, which have been developed for in vitro applications. According to the companies, the deal strengthens Taconic's tADMET portfolio of models, and expands Medicyte's distribution and market visibility, while at the same time providing entry into new markets for its hepatocyte cell strains.

The tADMET products are genetically and tissue humanized mouse cells and in vitro tools and services for improving the predictability of drug response in humans. Translational research applications for tADMET include studies in drug metabolism, toxicology and safety, and infectious diseases of the liver.

Financial and other terms of the deal were not disclosed.

"Human hepatocytes are indispensable for many applications in research, drug screening, and development," Joris Braspenning, managing director of Medicyte, said in a statement. "However, the availability of primary human hepatocytes is limited and their quality is variable. With the Upcyte hepatocytes, we can bring predictive, reliable, and standardized cells on the market to close the gap."

Medicyte, based in Heidelberg, Germany, develops controlled, scalable, and standardized human primary cell products. Taconic, located in New York's Hudson River Valley, provides genetically engineered mouse and rat models and services.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.